RC
TGTX icon

RegentAtlantic Capital’s TG Therapeutics TGTX Stock Holding History

RegentAtlantic Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,700
Closed -$227K – 644
2021
Q1 		$227K Buy
+4,700
New +$226K 0.01% 520

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

RegentAtlantic Capital's TGTX Position: Q2 2021 in Review

RegentAtlantic Capital sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 4,700 shares — an estimated $227K sold.

RegentAtlantic Capital first reported a position in TGTX in Q1 2021 and held it in 1 quarter. The position peaked at $227K in Q1 2021. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • RegentAtlantic Capital reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • RegentAtlantic Capital sold 4,700 TG Therapeutics shares in Q2 2021, an estimated $227K.
  • RegentAtlantic Capital first reported a position in TG Therapeutics in Q1 2021 and held it in 1 quarter.
  • RegentAtlantic Capital's TG Therapeutics position peaked at $227K in Q1 2021.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on RegentAtlantic Capital's 13F filing for Q2 2021, filed 12 Aug 2021.